-
Phase III XL184 vs Placebo for Unresectable, Locally Advanced or Metastatic Medullary Thyroid Cancer
Not Recruiting
More
The purpose of this research study is to evaluate the progression-free survival (PFS) with XL184 as compared with placebo (an inactive substance) in subjects with unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC). Subjects will be randomized to receive XL184 or placebo in a 2:1 ratio. XL184 is an investigational drug that inhibits VEGFR2, MET and RET, kinases implicated in tumor formation, growth and migration.
The Clinical Steering Committee for this study, comprised of study doctors who specialize in medullary thyroid cancer, has provided guidance regarding the design of the study. The committee includes: Douglas Ball, MD, Barry Nelkin, PhD, Martin Schlumberger, MD and Steven Sherman, MD.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ruth Lira, 6507231367.
Stanford Investigators
View full details
-
Phase Ib Topically-Applied AG013 in Induction Chemo for Head and Neck Cancers
Not Recruiting
More
The purpose of this study is to assess the safety and tolerability of AG013 (genetically modified L. lactis bacteria engineered to secrete human Trefoil Factor 1), and to explore the ability of AG013 to attenuate the course and severity of oral mucositis (OM) in subjects receiving induction chemotherapy for the treatment of head and neck cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ruth Lira, 6507231367.
Stanford Investigators
View full details
-
Phase II Rigosertib in Relapsed, Metastatic, Platinum-resistant, HPV + or - Squamous Cell Carcinoma
Not Recruiting
More
The primary objective of this study is to determine if tumors in patients with papillomavirus (HPV) positive or negative squamous cell carcinoma (SCC) that no longer responds to standard therapy will decrease in size following treatment with the investigational drug, rigosertib sodium (ON 01910.Na). A secondary objective is to determine if treatment with rigosertib causes any side effects.
Rigosertib is an investigational drug, which means that it has not been approved by the U.S. Food and Drug Administration (FDA) to treat any diseases. We are studying rigosertib as a new anticancer drug. Tests that we have done in the laboratory suggest that rigosertib works by blocking cell division in cancer cells and causing them to die.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ruth Lira, 650-723-1367.
Stanford Investigators
View full details
-
Phase I/IIa NovelSmallMolecule EBNA1 Inhibitor VK2019 in EBVirus+ NasopharyngealCancer & EBV-Cancers
Not Recruiting
More
VK-2019-001 is a 1/2a trial of the oral EBNA-1 targeting agent VK-2019 in patients with EBV-positive recurrent or metastatic NPC to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D), as well as to evaluate the PK profile of VK-2019.
Stanford is currently not accepting patients for this trial.
For more information, please contact Elizabeth Winters, 650-721-6509.
Stanford Investigators
View full details
-
Phase I ABBV-368 (Single Agent & Combination in Locally Advanced or Metastatic Solid Tumors
Not Recruiting
More
The primary purpose of this Phase 1, open-label study is to evaluate the safety, pharmacokinetics, and preliminary efficacy of ABBV-368 as a monotherapy and in combination with ABBV-181 in participants with locally advanced or metastatic solid tumors. The study will consist of 3 parts: ABBV-368 dose escalation, ABBV-368 tumor-specific dose expansion (triple negative breast cancer \[TNBC\] cohort and head and neck cancer cohort) and 18F-AraG Imaging Substudy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Phase II of TH-4000 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin
Not Recruiting
More
This phase 2 study is designed to evaluate the safety and activity of TH-4000, a hypoxia-activated prodrug in participants with recurrent or metastatic squamous cell carcinoma of the head and neck or skin.
Stanford is currently not accepting patients for this trial.
For more information, please contact Mary (Tookie) May, 650-721-4079.
Stanford Investigators
View full details
-
Phase II Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients with SCCHN
Not Recruiting
More
Docetaxel and cetuximab are FDA-approved for the treatment of squamous cell carcinoma of the head and neck (SCCHN). Cisplatin and carboplatin, while not FDA-approved for SCCHN, have been used as standard of care in SCCHN patients in combination with other drugs. This study evaluates if weekly cisplatin and docetaxel, in combination with cetuximab, is effective in palliative treatment of patients with SCCHN. These drugs will be given intravenously weekly, repeated 3 of every 4 weeks until evidence of disease progression or unacceptable adverse events.
Stanford is currently not accepting patients for this trial.
For more information, please contact Risa Jiron, 650-736-1598.
Lead Sponsor
Stanford Investigators
View full details
-
Phase 1b Urelumab + Cetuximab in Advanced / Metastatic CRC or SCCHN
Not Recruiting
More
The purpose of the study is to determine the safety, tolerability and maximum tolerated dose of Urelumab in combination with Cetuximab in patients with Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck.
Stanford is currently not accepting patients for this trial.
For more information, please contact Risa Jiron, 650-736-1598.
Stanford Investigators
View full details
-
SRF114-101: A Phase 1 Study Of CHS-114 In Participant With Advanced Solid Tumors
Recruiting
More
This is a Phase 1, open-label, first-in-human, dose-escalation and expansion study of CHS-114, a monoclonal antibody that targets CCR8, as a monotherapy in patients with solid tumors.
Stanford Investigators
View full details
-
Phase II Cemiplimab alone and in Combo w/ RP1 in Advanced Cutaneous Squamous Cell Carcinoma
Not Recruiting
More
To estimate the clinical benefit of cemiplimab monotherapy versus cemiplimab in combination with RP1 for patients with locally advanced or metastatic CSCC, as assessed by overall response rate (ORR) and complete response rate (CRR) according to blinded independent review.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Phase II IV GC4419 in Cisplatin + IMRT in Non-Metastatic Squamous Cell Carcinoma
Not Recruiting
More
The purpose of the phase 2, GT-201 clinical study is to determine if GC4419 administered prior to intensity-modulated radiation therapy (IMRT) reduces the incidence, duration, and severity of radiation induced oral mucositis in patients who have been diagnosed with locally advanced, non-metastatic squamous cell carcinoma of the head and neck.
Stanford is currently not accepting patients for this trial.
For more information, please contact Yeon Seung Koo, 650-721-4069.
Stanford Investigators
View full details
-
Phase 2 Study of Nivolumab and Ipilimumab with or without cabozantinib in patients with advanced NPC
Recruiting
More
This phase II trial tests how well nivolumab and ipilimumab immunotherapy with or without cabozantinib works in treating patients with nasopharyngeal cancer that has come back (after a period of improvement) (recurrent), has spread from where it first started (primary site) to other places in the body (metastatic), or for which no treatment is currently available (incurable). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Giving immunotherapy with nivolumab and ipilimumab and targeted therapy with cabozantinib may help shrink and stabilize nasopharyngeal cancer.
Stanford Investigators
View full details
-
Phase II Capecitabine in Advanced or Recurrent Squamous Cell Carcinoma of the Skin
Not Recruiting
More
Phase 2 evaluation of capecitabine in patients with advanced or recurrent squamous cell carcinoma of the skin.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ruth Lira, 650-723-1367.
Lead Sponsor
Stanford Investigators
View full details
-
Phase II Magrolimab Combination Therapy in Head and Neck Squamous Cell Carcinoma
Not Recruiting
More
The goals of this clinical study are to learn about the safety, tolerability, dosing and effectiveness of the study drug, magrolimab in combination with other anticancer therapies in patients with head and neck squamous cell carcinoma (HNSCC).
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Phase II REGN2810-Fully Human Monoclonal Anitbody to PD-1 in Advncd Cutaneous Squamous CellCarcinoma
Not Recruiting
More
The goals of this study are to evaluate the clinical benefit and safety of cemiplimab in participants with metastatic (nodal or distant) Cutaneous Squamous Cell Carcinoma (CSCC), or unresectable locally advanced CSCC.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Phase TBD Multicenter Cancer Biospecimen Collection Study
Recruiting
More
This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor biopsy. These specimens and clinical data may be used in subsequent studies for the development and validation of a diagnostic test.
Stanford Investigators
View full details
-
Pilot Sonidegib & BKM120 For the Treatment of Advanced Basal Cell Carcinomas
Not Recruiting
More
This pilot trial studies how well sonidegib and buparlisib work in treating patients with basal cell carcinoma that has spread to other places in the body. Sonidegib and buparlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Stanford is currently not accepting patients for this trial.
For more information, please contact Anne Lynn Chang, 650-721-7151.
Stanford Investigators
View full details
-
Phase Ib Pembrolizumab for Unresectable or Metastatic Basal Cell Carcinoma
Not Recruiting
More
This phase 1-2 trial studies how well pembrolizumab with or without vismodegib works in treating patients with skin basal cell cancer that has spread to other places in the body or cannot be removed by surgery. Monoclonal antibodies, such as pembrolizumab, are checkpoint inhibitors that stimulate immune response. Vismodegib may stop the growth of tumor cells by blocking signals needed for cell growth.
Stanford is currently not accepting patients for this trial.
For more information, please contact Anne Lynn Chang, 650-721-7151.
Stanford Investigators
View full details
-
Phase II REGN2810 in Advanced Basal Cell Carcinoma
Not Recruiting
More
The primary objective is to estimate the objective response rate (ORR) for metastatic Basal Cell Carcinoma (BCC) (group 1) and for unresectable locally advanced BCC (group 2) when treated with cemiplimab as a monotherapy
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Phase III Nivolumab vs Investigator's Choice in Recurrent/Metastatic Platinum-refractory SCCHN
Not Recruiting
More
The purpose of this study is to find out whether Nivolumab will significantly improve overall survival as compared to therapy of investigator's choice in patients with recurrent or metastatic head and neck carcinoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Risa Jiron, 650-736-1598.
Stanford Investigators
View full details
-
Phase II Induction Chemo then Cetuximab + Low/Standard Dose IMRT in HPV Resectable SCC of Oropharynx
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Radiation therapy uses high energy x-rays to kill tumor cells. Giving paclitaxel, cisplatin, and cetuximab together with radiation therapy may kill more tumor cells.
PURPOSE: This phase II trial is studying paclitaxel, cisplatin, and cetuximab to see how well they work when followed by cetuximab and two different doses of intensity-modulated radiation therapy in treating patients with HPV-associated stage III or stage IV cancer of the oropharynx that can be removed by surgery.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lauren Pernicka, 6507216977.
Stanford Investigators
View full details
-
Expanded Access Cabozantinib in Unresectable Locally Advanced/ Metastatic Medullary Thyroid Cancer
Not Recruiting
More
The objective of this study is to provide access to cabozantinib for eligible subjects with medullary thyroid cancer (MTC) pending approval of Exelixis' New Drug Application (NDA) by the FDA and commercial availability of cabozantinib.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ruth Lira, 650-723-1367.
Stanford Investigators
View full details
-
Phase I Atezolizumab (MPDL3280A) IV - Single Agent in Locally Advanced or Metastatic Solid Tumors
Not Recruiting
More
This Phase I, multicenter, first-in-human, open-label, dose-escalation study will evaluate the safety, tolerability, and pharmacokinetics of atezolizumab (MPDL3280A) administered as single agent to participants with locally advanced or metastatic solid malignancies or hematologic malignancies. The study will be conducted in two cohorts: Dose-escalation cohort and Expansion cohort.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Pitsiouni, 650-721-6977.
Stanford Investigators
View full details
-
Ph 1 Panitumumab-IRDye800 Optical Imaging Agent to Detect Head and Neck Cancer During Surgery
Not Recruiting
More
Phase I trial to evaluate the safety of escalating dose levels of conjugated panitumumab-IRDye800 in subjects with head and neck squamous cell carcinoma (HNSCC) that undergo surgery with curative intent.
Stanford is currently not accepting patients for this trial.
For more information, please contact Alifia Hasan, 650-721-4088.
Stanford Investigators
View full details
-
Phase II Pembrolizumab +/- BNT113 in HNSCC Which is HPV16+ and Expresses PD-L1
Not Recruiting
More
An open-label, controlled, multi-site, interventional, 2-arm, Phase II/III trial of BNT113 in combination with pembrolizumab vs pembrolizumab monotherapy as first line treatment in patients with unresectable recurrent or metastatic HPV16+ HNSCC expressing programmed cell death ligand-1 (PD-L1) with combined positive score (CPS) ≥1.
This trial has two parts.
Part A, is an initial non-randomized Safety Run-In Phase to confirm the safety and tolerability at the selected dose range level of BNT113 in combination with pembrolizumab.
Part B, is a randomized part to generate pivotal efficacy and safety data of BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy in the first line setting in patients with unresectable recurrent or metastatic HPV16+ HNSCC expressing PD-L1 with CPS ≥1. Patients included in the Safety Run-In Phase of the trial (Part A) will not be randomized to Part B and will continue on-trial treatment (BNT113 plus pembrolizumab) within Part A.
For Part B, an optional pre-screening phase is available for all patients where patients' tumor samples may be submitted for central HPV16 DNA and central PD-L1 expression testing prior to screening into the main trial.
Patients will be treated with BNT113 in combination with pembrolizumab or with pembrolizumab monotherapy for approximately up to 24 months.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Pilot Dabrafenib and Trametinib in BRAF Mutated Ameloblastoma
Not Recruiting
More
This pilot clinical trial studies dabrafenib and trametinib in treating patients with ameloblastoma and a specific mutation (change) in the BRAF gene. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Stanford is currently not accepting patients for this trial.
For more information, please contact Elizabeth Winters, 650-721-6509.
Lead Sponsor
Stanford Investigators
View full details
-
Phase II INCAGN01876 in Combination with Immunotherapy in Recurrent or Metastatic HNSCC
Not Recruiting
More
The purpose of this study is to determine the safety, tolerability, efficacy, PK and pharmacodynamics of INCAGN01876 when given in combination with retifanlimab. The study will consist of 2 parts: a safety lead-in part (Part 1) followed by a dose expansion part (Part 2).
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Phase III Platinum-Gemcitabine +/-Nivolumab in 1st-Line Recurrent/Metastatic NasopharyngealCarcinoma
Not Recruiting
More
This phase III trial compares the effect of adding nivolumab to the usual chemotherapy (cisplatin or carboplatin with gemcitabine) versus standard chemotherapy alone in treating patients with nasopharyngeal cancer that has come back (recurrent) or spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, carboplatin, and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab with the usual chemotherapy may work better than the standard chemotherapy alone in treating patients with nasopharyngeal cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Site Public Contact, 650-498-7061.
Stanford Investigators
View full details
-
Phase III Immunotherapy +/- Consolidative RT in Oligometastatic Head & Neck Squamous Cell Carcinoma
Not Recruiting
More
This phase III trial compares pembrolizumab with radiation therapy to pembrolizumab without radiation therapy (standard therapy) given after pembrolizumab plus chemotherapy for the treatment of patients with squamous cell carcinoma of the head and neck that has spread from where it first started (primary site) to other places in the body (metastatic). Pembrolizumab is a type of immunotherapy that stimulates the body's immune system to fight cancer cells. Pembrolizumab targets and blocks a protein called PD-1 on the surface of certain immune cells called T-cells. Blocking PD-1 triggers the T-cells to find and kill cancer cells. Radiation therapy uses high-powered rays to kill cancer cells. Giving radiation with pembrolizumab may be more effective at treating patients with metastatic head and neck cancer than the standard therapy of giving pembrolizumab alone.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Phase 0 Pilot off label use of Arsenic Trioxide for Basal Cell Carcinoma (BCC)
Not Recruiting
More
This pilot clinical trial studies arsenic trioxide in treating patients with basal cell carcinoma. Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stop them from dividing
Stanford is currently not accepting patients for this trial.
For more information, please contact Irene Bailey-Healy, 408-892-7261.
Lead Sponsor
Stanford Investigators
View full details
-
Phase I 1st-In-Human REGN2810 Programmed Death-1 Tx +/-Other Anti-Cancer Tx in Advanced Malignancies
Not Recruiting
More
This is a phase 1, open-label, multicenter, ascending-dose escalation study of cemiplimab, alone and in combination with other anti-cancer therapies in patients with advanced malignancies.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Phase I CUDC-101 with Concurrent Cisplatin and XRT in Locally Advanced HPV- Head & Neck Cancer
Not Recruiting
More
This is a phase I dose escalation study of CUDC-101 in combination with concurrent cisplatin and radiation therapy in patients with locally advanced head and neck cancer. CUDC-101 is a multi-targeted agent designed to inhibit epidermal growth factor receptor (EGFR), human epidermal growth factor receptor Type 2 (Her2) and histone deacetylase (HDAC). The study is designed to establish the safety, tolerability and maximum tolerated dose (MTD) of CUDC-101 when administered in combination with concurrent cisplatin and radiation over an 8-week treatment course, consisting of a one week run-in period of CUDC-101 administered alone, followed by seven weeks of combination treatment with CUDC-101, cisplatin and radiation therapy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ruth Lira, 6507231367.
Stanford Investigators
View full details
-
Phase Ib/II IPH2201 & Cetuximab in HPV (+) & HPV (-) Recurrent or Metastatic SCC of the Head & Neck
Not Recruiting
More
The objective of this study is to evaluate in a 3 +3 design, the safety of escalating doses of Monalizumab given IV in combination with cetuximab in patients who have received prior systemic regimen(s) for recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).
Cohorts expansion will evaluate antitumor activity of monalizumab and cetuximab with or without anti-PD(L)1
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Phase I to Evaluate Immunological Response to PD-(L)1 Inhibition in SquamousCellCarcinoma of the H&N
Not Recruiting
More
This is a single-center cross-sectional imaging and correlative biomarker study in patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN). Cohort 1 will be patients with unresectable or metastatic SCCHN cancer receiving standard of care (SOC) anti-PD-1 treatment and Cohort 2 will be neoadjuvant study participants who will receive one dose of anti-PD-1 treatment prior to tumor resection or radiation. Blood sampling and tissue biopsies will be collected from both cohorts and both cohorts will undergo two whole body PET(Positron Emission Tomography)/CT(Computed Tomography) imaging with \[18F\]F-AraG. First scan prior to initiating anti-PD-1 treatment and second scan post initiation of anti-PD-1 treatment in Cohort 1 and prior to tumor resection or radiation in Cohort 2
Stanford is currently not accepting patients for this trial.
For more information, please contact Stefania U Chirita, 650-723-1423.
Stanford Investigators
View full details
-
Phase II MEHD7945A vs Cetuximab in Recurrent / Metastatic HNSCC for Progression after Platinum Chemo
Not Recruiting
More
This phase II, open-label, randomized study will evaluate the efficacy and safety of MEHD7945A versus cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck who have progressed during or following platinum-based chemotherapy. Patients will be randomized to receive either MEHD7945A 1100 mg intravenously (iv) every 2 weeks or cetuximab 400 mg/m2 iv loading dose followed by 250 mg/m2 iv weekly. Patients treated with cetuximab (Arm B) may cross-over to MEHD7945A (Arm A) upon central confirmation of progressive disease and upon meeting eligibility criteria. Anticipated time on study treatment is until disease progression or intolerable toxicity occurs.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ruth Lira, 6507231367.
Stanford Investigators
View full details
-
Phase Ib GDC-0449 + Rosigilitazone or Oral Contraceptive in Locally Advanced/Metastatic Solid Tumors
Not Recruiting
More
This is a single-arm, multicenter, Phase Ib study designed to describe the effect of GDC-0449 on the pharmacokinetics of rosiglitazone and oral contraceptives in patients with advanced solid tumors who are refractory to treatment or for whom no standard therapy exists.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ruth Lira, 6507231367.
Stanford Investigators
View full details
-
Phase II Neoadjuvant &Adjuvant Tx IRX-2 Regimen in Newly Dx Stage II / III / IVA SCC of Oral Cavity
Not Recruiting
More
The purpose of this study is to determine whether a pre-operative regimen of the study drug, IRX-2, a human cell-derived biologic with multiple active cytokine components, plus a single dose of cyclophosphamide, followed by 21 days of indomethacin, zinc-containing multivitamins, and omeprazole is active in treatment of oral cavity cancer. The regimen is intended to stimulate an immune response against the cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Priya Hegde, 650-723-0920.
Stanford Investigators
View full details
-
Phase 1B/2 Tabelecleucel +/- Pembrolizumab in Recurrent Metastatic EBV in Nasopharyngeal Carcinoma
Not Recruiting
More
This is a multicenter, open-label, single-arm Phase 1B/2 study to assess the safety and efficacy of tabelecleucel in combination with pembrolizumab for the treatment of subjects with platinum-pretreated, recurrent/metastatic Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC).
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors
Not Recruiting
More
This is a prospective single-center, open label, pilot study to investigate the safety and efficacy of LDE225 in patients with locally advanced or metastatic basal cell carcinoma.
Primary Objectives:
• To explore the effects of oral LDE225 on the Progression Free Survival (PFS) of individuals with locally advanced or metastatic BCC who have been previously treated with a non-LDE225 Smo inhibitor.
Secondary Objectives:
* To evaluate the effect of oral LDE225 on tumor tissue biomarkers of BCC activation (Gii 1, 2, Patched 1,2 and Ki67) in individuals which are non-na"ive to Smo inhibitors other than LDE225, at baseline and at end-of-treatment
* To describe adverse effects of oral LDE225 in individuals with a history of non-LDE225 Smo inhibitor usage
* To assess the overall survival rates of individuals with locally advanced BCC or metastatic BCC who have previously taken a non-LDE225 Smo inhibitor after treatment with LDE225
Stanford is currently not accepting patients for this trial.
For more information, please contact Shruthi Rangaraj, 650-721-7159.
Stanford Investigators
View full details
-
BIBW 2992 (Afatinib) in Head & Neck Cancer
Not Recruiting
More
The primary objective of this study is to explore the efficacy of BIBW 2992 compared with cetuximab (Erbitux) in patients with metastatic or recurrent head and neck cancer after failure of platinum-containing therapy. In addition, the trial aims to clarify the influence of EGFR genotype on tumor response to the treatment regimens.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ruth Lira, 6507231367.
Stanford Investigators
View full details
-
Phase III Sorafenib vs Placebo in Local Advanced/Metastatic RAI-Refractory Differentiated Thyroid CA
Not Recruiting
More
Trial of sorafenib versus placebo in the treatment of locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine
Stanford is currently not accepting patients for this trial.
For more information, please contact Ruth Lira, 6507231367.
Stanford Investigators
View full details
-
Phase II Surgery + Low/Std Dose IMRT in Resectable p16+ Locally Advanced Oropharynx CA
Not Recruiting
More
This randomized phase II trial studies how well transoral surgery followed by low-dose or standard-dose radiation therapy works in treating patients with human papilloma virus (HPV) positive stage III-IVA oropharyngeal cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy with chemotherapy may kill any tumor cells that remain after surgery. It is not yet known how much extra treatment needs to be given after surgery.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ekaterina Dib, 650-723-0503.
Stanford Investigators
View full details
-
Phase Ib/II Nanatinostat &Valganciclovir in EBV+ ST & +/-Pembrolizumab in Nasopharyngeal Carcinoma
Recruiting
More
This study will evaluate the safety and efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive solid tumors and in combination with pembrolizumab in patients with recurrent/metastatic nasopharyngeal carcinoma
Stanford Investigators
View full details
-
Phase I LY2940680 in Advanced Cancer or Advanced Basal Cell Carcinoma
Not Recruiting
More
The purpose of this study is to find a recommended dose level and schedule of dosing LY2940680 that can safely be taken by participants with advanced cancer. The study will also explore the changes in a cancer marker level in skin, hair follicles, buccal cells, and tumor cells. Finally, the study will help document any antitumor activity this drug may have.
Stanford is currently not accepting patients for this trial.
For more information, please contact Anne Chang, 650-721-7151.
Stanford Investigators
View full details
-
Phase II/III Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus Deoxyribonucleic Acid
Not Recruiting
More
There are two study questions we are asking in this randomized phase II/III trial based on a blood biomarker, Epstein Barr virus (EBV) deoxyribonucleic acid (DNA) for locoregionally advanced non-metastatic nasopharyngeal cancer. All patients will first undergo standard concurrent chemotherapy and radiation therapy. When this standard treatment is completed, if there is no detectable EBV DNA in their plasma, then patients are randomized to either standard adjuvant cisplatin and fluorouracil chemotherapy or observation. If there is still detectable levels of plasma EBV DNA, patients will be randomized to standard cisplatin and fluorouracil chemotherapy versus gemcitabine and paclitaxel. Radiation therapy uses high energy x rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, fluorouracil, gemcitabine hydrochloride, and paclitaxel work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving cisplatin and fluorouracil is more effective than gemcitabine hydrochloride and paclitaxel after radiation therapy in treating patients with nasopharyngeal cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Polly Young, 650-497-7499.
Stanford Investigators
View full details
-
Phase III Radiotherapy + Cetuximab vs Chemotherapy in HPV-associated Oropharynx Cancer
Not Recruiting
More
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether radiation therapy is more effective with cisplatin or cetuximab in treating oropharyngeal cancer.
PURPOSE: This phase III trial is studying radiation therapy with cisplatin or cetuximab to see how well it works in treating patients with oropharyngeal cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Polly Young, 650-497-7499.
Stanford Investigators
View full details
-
Phase II 89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC
More
The purpose of this study is to determine the diagnostic utility of 89Zr-panitumumab to identify metastatic lesion(s) in subjects with head and neck squamous cell carcinoma (HNSCC).
Stanford Investigators
View full details
-
FNA Tumor Sampling for CD137 Modulation: A Pilot Study
Not Recruiting
More
The purpose of this study is to better understand the biology of the body's immune response to monoclonal antibody therapy for cancer. Your health information will be used to identify your tissues. The tissue we obtain may be useful for research or education, resulting in new drugs, therapies or diagnostic procedures.
Stanford is currently not accepting patients for this trial.
For more information, please contact Risa Jiron, 650-736-1598.
Lead Sponsor
Stanford Investigators
View full details
-
Phase 1b Nivolumab in Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
Not Recruiting
More
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Stanford is currently not accepting patients for this trial.
For more information, please contact Site Public Contact, 650-498-7061.
Stanford Investigators
View full details
-
Phase II Ipatasertib +/- Pembrolizumab in 1st Line Tx of Recurrent / Metastatic SCC of the Head&Neck
Not Recruiting
More
This phase II trial compares the effect of adding ipatasertib to pembrolizumab (standard immunotherapy) vs. pembrolizumab alone in treating patients with squamous cell cancer of the head and neck that has come back (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Ipatasertib is in a class of medications called protein kinase B (AKT) inhibitors. It may stop the growth of tumor cells and may kill them. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving ipatasertib in combination with pembrolizumab may be more effective than pembrolizumab alone in improving some outcomes in patients with recurrent/metastatic squamous cell cancer of the head and neck.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Phase II Pembrolizumab in Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)
Not Recruiting
More
The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) in adult participants with recurrent or metastatic(R/M) cutaneous Squamous Cell Carcinoma (cSCC) or locally advanced (LA) unresectable cSCC that is not amenable to surgery and/or radiation and/or systemic therapies.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Phase 3 of petosemtamab in incurable, metastatic/recurrent head and neck squamous cell carcinoma
Recruiting
More
This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.
Stanford Investigators
View full details
-
Phase II Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma
Not Recruiting
More
This phase 2 trial is studying whether giving a combination of docetaxel, cisplatin, and fluorouracil chemotherapy followed by the combination of cisplatin with radiation therapy works in treating patients with advanced nasopharyngeal cancer. Drugs used in chemotherapy, such as docetaxel, cisplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Giving combination chemotherapy together with radiation therapy may kill more tumor cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Risa Jiron, 650-736-1598.
Lead Sponsor
Stanford Investigators
View full details
-
Phase III of MEDI4736 Monotherapy or MEDI4736 + Tremelimumab vs SoC in SCCHN
Not Recruiting
More
This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus SoC therapy in the target patient population.
Stanford is currently not accepting patients for this trial.
For more information, please contact Mary (Tookie) May, 650-721-4079.
Stanford Investigators
View full details
-
Phase III Pembrolizumab vs Placebo as in HighRisk Locally Advanced Cutaneous Squamous Cell Carcinoma
Not Recruiting
More
This is a randomized, double-blind, study that compares pembrolizumab (MK-3475) with placebo given as adjuvant therapy in participants with high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) that have undergone surgery with curative intent in combination with radiotherapy. The primary hypothesis is that pembrolizumab is superior to placebo in increasing recurrence free survival (RFS).
Stanford is currently not accepting patients for this trial.
For more information, please contact Study Coordinator, 650-498-5185.
Stanford Investigators
View full details
-
Ph 1 Cetuximab-IRDye800 as an Optical Imaging Agent to Detect Cancer During Surgical Procedures
Not Recruiting
More
This study is an open label, single institution, Phase 1 dose-escalation study to determine the safety profile of cetuximab-IRDye800 used in subjects with head and neck squamous cell carcinoma (HNSCC) that undergo surgery with curative intent. Participants will be given a dose of an approved head and neck cancer drug (Cetuximab) along with an investigational study drug called Cetuximab-IRDye800. Cetuximab-IRDye800 is a drug that is given prior to surgery that attaches to cancer cells and appears to make them visible to the doctor when he uses a special camera during the operation. The investigators are evaluating whether or not the use of the study drug along with the special camera will better identify the cancer while patients are in the operating room.
Stanford is currently not accepting patients for this trial.
For more information, please contact Alifia Hasan, 650-721-4088.
Stanford Investigators
View full details
-
Phase III Gemcitabine & Carboplatin +/- Autologous EBV Cytotoxic T Cells in Nasopharyngeal Carcinoma
Not Recruiting
More
This study is a multi-center, randomized, open label, Phase III clinical trial for advanced Nasopharyngeal Carcinoma(NPC) Patients.
Drugs used in chemotherapy, such as gemcitabine and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving an infusion of a person's cytotoxic T cells (CTL) that have been treated in the laboratory may help the body build an effective immune response to kill tumor cells. Giving combination chemotherapy together with laboratory-treated T cells may kill more tumor cells. This Phase III trial is to assess if combined gemcitabine-carboplatin (GC) followed by adoptive T-cell therapy would improve clinical outcome for patients with advanced nasopharyngeal carcinoma (NPC). It is also the world's first, and largest, Phase 3 T-cell therapy cancer trial ever conducted, and enrollment is ongoing for 330 patients from 30 hospital centers across Asia and the United States.
This clinical trial is conducted on the back of a successful Phase 2 NPC trial involving 38 patients at the National Cancer Centre, Singapore. This trial produced the best published 2-year (62.9%), and median overall survival (OS) data (29.9 months) in 35 patients with advanced NPC who received autologous EBV-specific CTL. Kindly see https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978790/ for the Phase 2 publication titled "Adoptive T-cell Transfer and Chemotherapy in the First line treatment of Metastatic and/or Locally Recurrent Nasopharyngeal Carcinoma".
Stanford is currently not accepting patients for this trial.
For more information, please contact Uma R Swathee, 650-721-4079.
Stanford Investigators
View full details
-
Phase II in p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
Not Recruiting
More
This randomized phase II trial studies the side effects and how well modestly reduced-dose intensity-modulated radiation therapy (IMRT) with or without cisplatin works in treating patients with oropharyngeal cancer that has spread to other places in the body (advanced). Radiation therapy uses high energy x rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether IMRT is more effective with or without cisplatin in treating patients with oropharyngeal cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Polly Young, 650-497-7499.
Stanford Investigators
View full details
-
Phase III Nivolumab in Combo w/Ipilimumab vs Cetuximab +Cisplatin/Carboplatin +Fluorouracil in SCCHN
Not Recruiting
More
The main purpose of this study is to compare nivolumab and ipilimumab with the extreme regimen as first line treatment in patients with recurrent or metastatic squamous cell of the head and neck cancer
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Phase I CUE-101+/-Pembrolizumab in HPV16+ Recurrent/Metastatic Head&Neck SquamousCellCarcinoma(HNSCC
Not Recruiting
More
This is a multi-center, open-label, phase 1 dose escalation and expansion study evaluating the safety, anti-tumor effect, and immunogenicity of CUE-101 as monotherapy treatment in second line or CUE-101 Combination Therapy with Pembrolizumab in first line patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Stanford is currently not accepting patients for this trial.
For more information, please contact Elizabeth Winters, 650-721-6509.
Stanford Investigators
View full details
-
Phase II GSK1363089 for Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
Not Recruiting
More
This study is being conducted to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in adult subjects with squamous cell carcinoma of the head and neck (SCCHN). GSK1363089 is a new chemical entity that inhibits multiple receptor tyrosine kinases (RTKs) with growth-promoting and angiogenic properties. The primary targets of GSK1363089 are the HGF and vascular endothelial growth factor (VEGF) RTK families (eg, MET, VEGFR2/kinase insert domain receptor \[KDR\]). Since MET overexpression has been associated with poorer prognosis and MET tyrosine kinase mutations have been reported in SCCHN, inhibition of MET receptor and VEGFR2/KDR activation by agents such as GSK1363089 may be of therapeutic benefit in this patient population.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ruth Lira, 6507231367.
Stanford Investigators
View full details
-
Phase 1/2 Ad/PNP-F-araAMP+Co-Admin of Fludarabine Phosphate in Recurrent Local Head &Neck Cancer
Not Recruiting
More
Primary Objective: The primary objective of the study is to evaluate the safety of repeat administration of a dose level of Ad/PNP plus fludarabine phosphate (F-araAMP) which demonstrated anti-tumor activity in patients with advanced head and neck cancer in a completed phase I study.
Secondary Objective: The secondary objective is to evaluate the antitumor activity of repeat administration of Ad/PNP plus F-araAMP.
FDA Office of Orphan Drugs Division is a source of funding for the overall project.
Stanford is currently not accepting patients for this trial.
For more information, please contact Stefania U Chirita, 650-723-1423.
Stanford Investigators
View full details
-
Biopsy of Human Tumors for Cancer Stem Cell Characterization: A Feasibility Study
Not Recruiting
More
To see if a limited sampling of tumor tissue from human subjects is a feasible way to gather adequate tissue for cancer stem cell quantification.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ruth Lira, 650-723-1367.
Lead Sponsor
Stanford Investigators
View full details
-
Phase I Safety Testing Nivolumab +Chemotherapy in Intermediate &High-Risk Advanced Head &Neck Cancer
Not Recruiting
More
This study will evaluate the safety of adding nivolumab to several chemotherapy platforms with weekly cisplatin, high-dose cisplatin, cetuximab or radiation therapy alone.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Oral Arsenic Trioxide and Itraconazole in Advanced Basal Cell Carcinoma
Not Recruiting
More
This pilot clinical trial studies how well arsenic trioxide and itraconazole work in treating patients with basal cell cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Itraconazole may help treat fungal infections in patients with basal cell cancer. Giving arsenic trioxide with itraconazole may work better in treating basal cell cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Irene Bailey-Healy, 408-892-7261.
Stanford Investigators
View full details
-
Phase II EBNA1 Inhibitor VK 2019 in EBV Positive Nasopharyngeal Cancer &Other EBV AssociatedCancers
Not Recruiting
More
To evaluate the anti cancer effect of VK 2019 in subjects with EBV related nasopharyngeal carcinoma (NPC) for whom there is no other standard treatment available
Stanford is currently not accepting patients for this trial.
For more information, please contact Elizabeth Winters, 650-723-6372.
Lead Sponsor
Stanford Investigators
View full details
-
Phase II Nivolumab +/-BMS-986016(Relatlimab) in Recurrent/Metastatic Nasopharyngeal Carcinoma
Recruiting
More
This phase II trial tests the addition of BMS-986016 (relatlimab) to the usual immunotherapy after initial treatment for nasopharyngeal cancer that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Relatlimab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. The usual approach of treatment is initial treatment with chemotherapy such as the combination of cisplatin (or carboplatin) and gemcitabine, along with immunotherapy such as nivolumab. After the initial treatment is finished, patients may continue to receive additional immunotherapy. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid (DNA) and may kill cancer cells. Giving BMS-986016 in addition to the usual immunotherapy after initial treatment may extend the time without the tumor cells growing or spreading longer than the usual approach in patients with recurrent or metastatic nasopharyngeal cancer.
Stanford Investigators
View full details
-
Phase I/II Anti-CD27 Antibody(Varlilumab) + Anti-PD-1(Nivolumab) in Advanced Refractory Solid Tumors
Not Recruiting
More
This is a study to determine the clinical benefit (how well the drug works), safety, and tolerability of combining varlilumab and nivolumab (also known as Opdivo® , BMS-936558). Both drugs target the immune system and may act to promote anti-cancer effects.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Phase III Pembrolizumab +/- Petosemtamab in First-LineTreatment of Recurrent/Metastatic PD-L1+ HNSCC
Recruiting
More
This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.
Stanford Investigators
View full details
-
Phase I/Ib Ciforadenant Single Agent & Combo w/ Atezolizumab in Selected Incurable Cancers
Not Recruiting
More
This is a phase 1/1b open-label, multicenter, dose-selection study of ciforadenant, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of ciforadenant as a single agent and in combination with atezolizumab, a PD-L1 inhibitor against various solid tumors. Ciforadenant blocks adenosine from binding to the A2A receptor. Adenosine suppresses the anti-tumor activity of T cells and other immune cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Phase III Cabozantinib (XL184) in Radioiodine-Refractory Differentiated Thyroid Cancer
Not Recruiting
More
The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid Cancer (DTC) who have progressed after prior vascular endothelial growth factor receptor (VEGFR)-Targeted therapy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Phase II PR-104 in Treatment Naïve and Sensitive-relapse Small Cell Lung Cancer
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy, such as PR-104, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
PURPOSE: This phase II trial is studying how well PR-104 works in treating patients with previously untreated or relapsed small cell lung cancer (SCLC).
Stanford is currently not accepting patients for this trial.
For more information, please contact Ruth Lira, 6507231367.
Stanford Investigators
View full details
-
Imaging and Biomarkers of Hypoxia in Solid Tumors
Not Recruiting
More
Hypoxia, meaning a lack of oxygen, has been associated strongly with a wide range of human cancers. Hypoxia occurs when tumor growth exceeds the ability of blood vessels to supply the tumor with oxygenated blood. It is currently understood that hypoxic tumors are more aggressive. Current methods for measuring hypoxia include invasive procedures such as tissue biopsy, or insertion of an electrode into the tumor. EF5-PET may be a non-invasive way to measure tumor hypoxia.
Stanford is currently not accepting patients for this trial.
For more information, please contact Justin Carter, 650-725-4796.
Lead Sponsor
Stanford Investigators
View full details
-
Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
Recruiting
More
The goal of this clinical trial is to assess the safety and tolerability of a virus replicon particle (VRP) encapsulated saRNA encoding IL-12 when injected into Squamous Cell Carcinomas in head and neck cancer patients. The main questions being addressed are:
The safety and tolerability of intratumoral (IT) injections of VRP-encapsulated saRNA encoding IL-12 (VLPONC-01)
The tumor response to IT injections of VLPONC-01
The tumor response due to the combination of IT injections of VLPONC-01 and system IV administration of neoadjuvant pembrolizumab (anti-PD-1) treatment
Researchers will compare neoadjuvant pembrolizumab alone to the combination therapy to see if the combination enhances tumor responses.
Stanford Investigators
View full details
-
Gemcitabine + Docetaxel + Toripalimab(GDT) Induction in EBV Associated Nasopharyngeal Carcinoma(NPC)
Recruiting
More
The purpose of the research is to test the safety and efficacy of the investigational drug in human subjects with cancer.
Lead Sponsor
Stanford Investigators
View full details
-
Phase II/III Adjuvant RT w/Cisplatin Docetaxel-Cetuximab or Cisplatin-Atezolizumab in HighRisk HNSCC
Not Recruiting
More
This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to compare the usual treatment (radiation therapy with cisplatin chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy, and using the usual treatment plus an immunotherapy drug, atezolizumab.
Stanford is currently not accepting patients for this trial.
For more information, please contact Polly Young , 650-497-7499.
Stanford Investigators
View full details
-
Phase II Ozuriftamab Vedotin (BA3021) in PD-1/L1 Failure Patients w/ Recurrent or Metastatic SCCHN
More
This is a multi-center, open-label Phase 2 study designed to evaluate the efficacy and safety of BA3021 as monotherapy and combination therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Stanford Investigators
View full details
